On Thursday, T. Rowe Price Group Inc (NASDAQ:TROW)’s shares declined -0.85% to $78.06.
T.Rowe Price Group Inc (TROW)’s Retirement Saving & Spending Study revealed that a national sample of 1,505 millennials with 401(k)s have relatively good financial habits, particularly when compared with a national sample of 514 baby boomers with 401(k)s. While millennials are not saving at least 15% of their annual salary for retirement, as T. Rowe Price recommends, they recognize that saving for retirement is important and are interested in saving more.
More millennials than baby boomers track expenses carefully (75% vs. 64%) and stick to a budget (67% vs. 55%). And while baby boomers on average are saving a slightly higher percentage of their salary for retirement than millennials are saving, more millennials have raised their retirement savings within the past 12 months (40% vs. 21%). This suggests that they are acting in accordance with their financial priorities, as millennials ranked contributing to a 401(k) but below the match and paying down debt equally as their top priority.
T.Rowe Price Group, Inc. is a publicly owned asset administration holding company. The firm provides its services to individuals, institutional investors, retirement plans, financial intermediaries, and institutions. Through its auxiliaries, it launches and manages equity and fixed income mutual funds. The firm also launches balanced mutual funds and private equity funds.
Lion Biotechnologies Inc (NASDAQ:LBIO)’s shares dropped -4.57% to $9.18.
Lion Biotechnologies Inc (LBIO granted orphan status to the company’s lead product candidate, LN-144, for the treatment of stage 2b to stage 4 malignant melanoma.
The FDA grants orphan status to novel drugs or biologics to treat rare medical diseases or conditions that affect fewer than 200,000 people in the United States. By receiving this designation for LN-144, Lion will be eligible for tax credits for clinical testing, exemption from a prescription drug user fee, and seven years of market exclusivity.
Lion Biotechnologies, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient’s immune system to eradicate cancer cells. The company’s lead product comprises LN-144, an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients tumors for the treatment of patients with refractory metastatic melanoma.
Lion Biotechnologies, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient’s immune system to eradicate cancer cells. The company’s lead product comprises LN-144, an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients tumors for the treatment of patients with refractory metastatic melanoma.
At the end of Thursday’s trade, Illumina, Inc. (NASDAQ:ILMN)‘s shares dipped -0.53% to $219.00.
BioMed Realty Trust, Inc. (BMR) declared that Illumina, Inc. (ILMN), a world leader in genomics focused on improving human health by unlocking the power of the genome, has signed a 20-year lease for a 155,000 square foot new and innovative scientific research building in Cambridge, England. The project will provide Illumina a collaborative environment and access to the highly skilled workforce in the dynamic research cluster anchored by Cambridge University.
The project advances state-of-the-art design, with plans to be able to seamlessly expand by 70,000 square feet into a 225,000 square foot building. BioMed Realty attained the land for the project from The Welding Institute under a long term ground lease, enlarging BioMed Realty’s Granta Park campus in Cambridge, England.
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. The companys products comprise sequencing platforms that are based on its SBS technology, which provides researchers with various ranges of applications and the ability to sequence mammalian genomes; and array platforms comprise of HiScan and iScan systems, in addition to NextSeq 550 system that are array scanners for DNA and RNA analysis applications, counting single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis.
SolarCity Corp (NASDAQ:SCTY), ended its Thursday’s trading session with -1.14% loss, and closed at $56.36.
SolarCity Corp (SCTY) the nation’s #1 solar power provider, and Minnetonka-based solar developer Sunrise Energy Ventures have partnered to create a new community solar program offering that allows renters, schools, municipalities and other current Xcel Energy customers to purchase renewable energy without installing solar panels on their properties. Minnesota’s new community solar program is mandated by law and is expected to be the largest in the nation when completed.
According to GTM Research and SEIA’s Q1 2015 U.S. Solar Market Insight Report, only 66MW(DC) of community solar projects are operating in the United States today. SolarCity’s new community solar program will develop a series of up to one-hundred 1MW(AC) community solar installations, or “gardens,” in Wright and Sherburne counties. SolarCity will then invite renters, low-income housing residents, schools, and others in the Minneapolis-St. Paul area to enter subscriber agreements to purchase the solar power the gardens produce at a rate of 13 cents per kWh. For up to 25 years, Xcel Energy will credit the subscribers at a rate of 14.7 kWh for each kWh of electricity that is purchased from SolarCity through a solar garden subscriber agreement. The anticipated 11.5 percent savings will be immediate for subscribers, who will remain Xcel Energy customers.
SolarCity Corporation designs, manufactures, installs, maintains, monitors, leases, and sells solar energy systems to residential, commercial, government, and other customers in the United States. It offers solar energy systems; solar lease and power purchase agreement finance products; mounting hardware for photovoltaic panels; and related software, in addition to develops a proprietary battery administration system, which is designed to enable remote, bidirectional control of distributed energy storage that can provide benefits to customers, utilities, and grid operators.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
